Uplizna
New Uplizna data drop in myasthenia gravis, while clock ticks on IgG4 decision
Uplizna, Myasthenia Gravis, Effectiveness, Improvement
Amgen’s Uplizna Achieves Phase 3 Success in Treating Immunoglobulin G4-Related Disease, Paving Way for Label Expansion
Amgen, Uplizna, Phase 3, Immunoglobulin G4-Related Disease, IgG4-RD, Rare Autoimmune Disease, Label Expansion
Amgen’s Uplizna Achieves Success in Phase 3 Trial for Immunoglobulin G4-Related Disease (IgG4-RD)
Amgen, Uplizna, IgG4-RD, Phase 3 Trial, Autoimmune Disease, Neuromyelitis Optica Spectrum Disorder (NMOSD)